KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy … – MarketWatch (press release)

KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy
MarketWatch (press release)
Ecallantide for Treatment of Acute Attacks of Acquired C1 Esterase Inhibitor Deficiency — Nisha S. Patel, MD, Asthma Allergy & Pulmonary Associates,
KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy istockAnalyst.com (press release)

all 14 news articles »

View full post on asthma – Google News

Clinical Data, Inc. Presents Data from Phase I Studies of Stedivaze(TM … – MarketWatch (press release)

Clinical Data, Inc. Presents Data from Phase I Studies of Stedivaze(TM
MarketWatch (press release)
Currently available adenosine agonists must be used with caution or are contraindicated in patients with asthma and COPD. The findings, presented at the
Clinical Data Reveals Positive Results From Early-stage Trials Of Stedivaze Stock Markets Review

all 13 news articles »

View full post on asthma – Google News

Glaxo, Theravance report Relovair safety data – BusinessWeek

Glaxo, Theravance report Relovair safety data
BusinessWeek
GlaxoSmithKline PLC and Theravance Inc. said Wednesday their lung disease and asthma drug Relovair met its goals in a mid-stage safety study.
GSK and Theravance announce combination ICS/LABA Phase II results in the MarketWatch (press release)
GlaxoSmithKline Reports Positive Results For Phase II Trial Of Relovair In RTT News
Theravance Announces Results From Phase II Study For Developmental Combination Stock Markets Review

all 31 news articles »

View full post on asthma – Google News